Biomarker evaluation demonstrates extracellular miRNA alterations in Parkinson's disease, highlighting opportunities for targeted patient stratification.
Mutations in the Leucine Rich Repeat Kinase 2 gene are highly relevant in both sporadic and familial cases of Parkinson's disease. Specific therapies are entering clinical trials but patient stratification remains challenging. Dysregulated microRNA expression levels have been proposed as biomarker candidates in sporadic Parkinson's disease.
No takes yet. Share an insight, caveat, or question.
Braunger et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: